Kamil KAYNAK, Ezel ERŞEN, Ahmet DEMİRKAYA, Berrak AKGÖZ, Büge ÖZ, Murat KARA

Akciğer evre I epidermoid karsinomlu olgularda otokrin hareket faktör reseptörü varlığınının sağkalıma etkisi

Giriş: Çalışmamızda, evre I skuamöz hücreli karsinomlu hastalarda otokrin hareket faktör reseptörü (OHFR) varlığı ve bunun sağkalım ile ilişkisi araştırıldı. Çalışma planı: Çalışmaya akciğerde evre I skuamöz hücre karsinomu saptanan 30 hasta (23 erkek, 7 kadın; ort. yaş 60±10; dağılım 33-77) alındı. Olguların hiçbiri ameliyat öncesi veya sonrasında kemoterapi veya radyoterapi görmemişti. Ameliyat sonrasında hastalar ortalama 48±11 ay takip edildi. Parametrelerin kıyaslanmasında ki-kare testi kullanıldı. Sağkalım analizi Kaplan-Meier yöntemiyle yapıldı ve istatistiksel farklar log-rank testi ile doğrulandı. Sağkalım üzerine OHFR ve klinik özelliklerin etkisini değerlendirmek için tekdeğişkenli ve çokdeğişkenli Cox regresyon analiz modeli kullanıldı.Bulgular: Altı hastada (%20) OHFR için boyama pozitif bulundu. Tüm sağkalım, OHFR pozitif olan hastalarda negatif olanlara kıyasla anlamlı derecede kötü bulundu (p=0.052). Çokdeğişkenli analizde OHFR pozitifliği (p

The effect of the presence of autocrine motility factor receptor on survival in patients with stage I epidermoid lung cancer

Background: We aimed to investigate the existence of autocrine motility factor receptor (AMFR) and its effect on survival in patients with stage I squamous cell carcinoma. Methods: The study included 30 patients (23 males, 7 females; mean age 60±10 years; range 33 to 77 years) with stage I squamous cell carcinoma of the lung. None of the patients received chemotherapy or radiotherapy before or after surgery. The mean follow-up period was 48±11 months. The chi-square test was used for comparison of variables. The cumulative survival rates were calculated by the Kaplan-Meier method and the significance was assessed by the log-rank test. The effects of AMFR and clinical factors on survival were assessed by univariate and multivariate analyses using Cox’s proportional hazard model.Results: Six tumors (20%) showed positive staining for AMFR. The overall survival in patients with AMFR expression was significantly worse than those without AMFR expression (p=0.052). Multivariate analysis showed AMFR expression (p

PDF

___

1) Auerbach O, Stout Ap, Hammond Ec, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961;265:253-67.
2) Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
3) Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, et al. Postrecurrent survival of patients with non-smallcell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994;108:158-61.
4) Volk T, Geiger B, Raz A. Motility and adhesive properties of high- and low metastatic murine neoplastic cells. Cancer Res 1984;44:811-24.
5) Partin AW, Schoeniger JS, Mohler JL, Coffey DS. Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A 1989;86:1254-8.
6) Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986;83:3302-6.
7) Rosen EM, Goldberg ID. Protein factors which regulate cell motility. In Vitro Cell Dev Biol 1989;25:1079-87.
8) Nakamori S, Watanabe H, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 1994;74:1855-62.
9) Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübben H, et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 1994;54:3120-3.
10) Maruyama K, Watanabe H, Shiozaki H, Takayama T, Gofuku J, Yano H, et al. Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int J Cancer 1995;64:316-21.
11) Hirono Y, Fushida S, Yonemura Y, Yamamoto H, Watanabe H, Raz A. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Br J Cancer 1996;74:2003-7.
12) Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
13) Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res 1990;50:409-14.
14) Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 1991;51:3507 11.
15) Watanabe H, Carmi P, Hogan V, Raz T, Silletti S, Nabi IR, et al. Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 1991; 266:13442-8.
16) Yelian FD, Liu A, Todt JC, Lei J, Qureshi F, Jacques SM, et al. Expression and function of autocrine motility factor receptor in human choriocarcinoma. Gynecol Oncol 1996;62:159-65.
17) Watanabe H, Shinozaki T, Raz A, Chigira M. Expression of autocrine motility factor receptor in serum- and protein-independent fibrosarcoma cells: implications for autonomy in tumor-cell motility and metastasis. Int J Cancer 1993;53:689-95.
18) Read RC, Yoder G, Schaeffer RC. Survival after conservative resection for T1 N0 M0 non-small cell lung cancer. Ann Thorac Surg 1990;49:391-8.
19) Padilla J, Calvo V, Penalver JC, Sales G, Morcillo A. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg. 1997;63:324-6.
20) LoCicero III J, Ponn RB, Daly BDT. Surgical treatment of nonsmall cell lung cancer. In: Shields TW, LoCicero III J, Ponn RB, editors. General thoracic surgery. Vol. 1, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1311-41.
21) Miller DL, Rowland CM, Deschamps C, Allen MS, Trastek VF, Pairolero PC. Surgical treatment of non-small cell lung cancer 1 cm or less in diameter. Ann Thorac Surg 2002; 73:1545-50.
22) Putnam Jr JB. Postresection follow-up for non-small cell lung cancer. In: Pearson FG, Cooper JD, Deslauriers J, Ginsberg RJ, Hiebert CA, Patterson GA, et al., editors. Thoracic surgery. 2nd ed. Philadelphia: Churchill Livingstone; 2002. p. 918-24.
23) Porrello C, Alifano M, Forti Parri SN, Sanna S, Lacava N, Corneli G, et al. Surgical treatment of stage I lung cancer. Results and prognostic factors. J Cardiovasc Surg 2002;43: 723-7.
24) Sagawa M, Saito Y, Takahashi S, Usuda K, Kamma K, Sato M, Ota S, Nagamoto N, Fujimura S, Nakada T, et al. Clinical and prognostic assessment of patients with resected small peripheral lung cancer lesions. Cancer 1990 15;66:2653-7.
25) Yamamoto K, Padilla Alarcón J, Calvo Medina V, García- Zarza A, Pastor Guillen J, Blasco Armengod E, et al. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. Eur J Cardiothorac Surg 2003;23:21-5.
26) Kara M, Ohta Y, Tanaka Y, Oda M, Watanabe Y. Autocrine motility factor receptor expression in patients with stage-I non-small cell lung cancer. Ann Thorac Surg 2001;71:944-8.
27) Inoue K, Sato M, Fujimura S, Sakurada A, Takahashi S, Usuda K, et al. Prognostic assessment of 1310 patients with nonsmall- cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 1998;116: 407-11.
28) Goldstraw P: Meeting summary: report on the international workshop on intrathoracic staging. London, October 1996. Lung Cancer 1997;18:107-111.
29) Watanabe Y, Shimizu J, Oda M, Hayashi Y, Iwa T, Nonomura A, et al. Proposals regarding some deficiencies in the new international staging system for non-small cell lung cancer. Jpn J Clin Oncol 1991;21:160-8.
30) Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996;2:1411-6.